Tema Etfs LLC Purchases Shares of 85,761 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Tema Etfs LLC acquired a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 85,761 shares of the company's stock, valued at approximately $1,087,000. Tema Etfs LLC owned about 0.09% of Day One Biopharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. FMR LLC lifted its stake in Day One Biopharmaceuticals by 73.9% in the fourth quarter. FMR LLC now owns 12,887,467 shares of the company's stock worth $163,284,000 after purchasing an additional 5,475,087 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Day One Biopharmaceuticals by 0.3% during the fourth quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company's stock valued at $49,197,000 after buying an additional 13,320 shares during the last quarter. Estuary Capital Management LP increased its holdings in shares of Day One Biopharmaceuticals by 35.5% in the fourth quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company's stock worth $47,092,000 after buying an additional 972,997 shares during the period. Pictet Asset Management Holding SA increased its holdings in shares of Day One Biopharmaceuticals by 17.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company's stock worth $44,219,000 after buying an additional 507,398 shares during the period. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $31,829,000. Hedge funds and other institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock traded down $0.29 during mid-day trading on Wednesday, reaching $6.29. 1,142,650 shares of the company's stock traded hands, compared to its average volume of 1,112,142. Day One Biopharmaceuticals, Inc. has a 12 month low of $6.08 and a 12 month high of $16.76. The firm has a 50 day moving average price of $7.36 and a two-hundred day moving average price of $10.68. The firm has a market capitalization of $637.57 million, a PE ratio of -6.11 and a beta of -1.24.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to analysts' expectations of $30.28 million. As a group, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Charles N. York II sold 4,282 shares of the stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $26,805.32. Following the completion of the sale, the chief financial officer now owns 265,231 shares in the company, valued at approximately $1,660,346.06. This trade represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jeremy Bender sold 13,964 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.26, for a total value of $87,414.64. Following the sale, the chief executive officer now directly owns 145,737 shares in the company, valued at $912,313.62. This trade represents a 8.74% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,725 shares of company stock valued at $167,299. 6.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

DAWN has been the topic of several analyst reports. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday, March 25th. Needham & Company LLC decreased their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Wedbush reaffirmed an "outperform" rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of "Buy" and an average price target of $30.57.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.